Technical Analysis for ACST - Acasti Pharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
1.11 | 0.91% | 0.01 |
ACST closed up 0.91 percent on Friday, January 18, 2019, on 56 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical ACST trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | Wide Bands | Range Expansion | 0.00% |
| Jan 18 | Overbought Stochastic | Strength | 0.00% |
| Jan 18 | Up 3 Days in a Row | Strength | 0.00% |
| Jan 17 | 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.91% |
| Jan 17 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.91% |
| Jan 17 | Wide Bands | Range Expansion | 0.91% |
| Jan 17 | Overbought Stochastic | Strength | 0.91% |
| Jan 16 | 1,2,3 Pullback Bullish | Bullish Swing Setup | 1.83% |
| Jan 16 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.83% |
| Jan 16 | Wide Bands | Range Expansion | 1.83% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2017-10-10
- Sector: Healthcare
- Industry: Pharmaceuticals
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for abnormalities in blood lipids, and the treatment and prevention of cardiovascular disorders. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ACST news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 1.8 |
| 52 Week Low | 0.43 |
| Average Volume | 595,963 |
| 200-Day Moving Average | 0.7745 |
| 50-Day Moving Average | 0.8113 |
| 20-Day Moving Average | 0.9258 |
| 10-Day Moving Average | 1.067 |
| Average True Range | 0.0715 |
| ADX | 40.24 |
| +DI | 34.9625 |
| -DI | 12.2839 |
| Chandelier Exit (Long, 3 ATRs ) | 0.9355 |
| Chandelier Exit (Short, 3 ATRs ) | 0.8745 |
| Upper Bollinger Band | 1.2495 |
| Lower Bollinger Band | 0.6021 |
| Percent B (%b) | 0.78 |
| BandWidth | 69.92871 |
| MACD Line | 0.0982 |
| MACD Signal Line | 0.0782 |
| MACD Histogram | 0.02 |
| Fundamentals | Value |
|---|---|
| Market Cap | 16.33 Million |
| Num Shares | 14.7 Million |
| EPS | -0.77 |
| Price-to-Earnings (P/E) Ratio | -1.44 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 1.22 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.23 | ||||
| Resistance 3 (R3) | 1.23 | 1.18 | 1.21 | ||
| Resistance 2 (R2) | 1.18 | 1.15 | 1.19 | 1.20 | |
| Resistance 1 (R1) | 1.15 | 1.13 | 1.17 | 1.15 | 1.20 |
| Pivot Point | 1.10 | 1.10 | 1.11 | 1.11 | 1.10 |
| Support 1 (S1) | 1.07 | 1.07 | 1.09 | 1.07 | 1.02 |
| Support 2 (S2) | 1.02 | 1.05 | 1.03 | 1.02 | |
| Support 3 (S3) | 0.99 | 1.02 | 1.01 | ||
| Support 4 (S4) | 0.99 |
